# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Mizuho analyst Uy Ear downgrades Avrobio (NASDAQ:AVRO) from Buy to Neutral and lowers the price target from $5 to $2.
Wells Fargo analyst Yanan Zhu maintains Avrobio (NASDAQ:AVRO) with a Overweight and lowers the price target from $2.5 to $2.
Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to preven...